Business
Present at the 14th Annual Biotech in Europe Forum
Present at the 14th Annual Biotech in Europe Forum.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9199S Scancell Holdings Plc 30 September 2014 \n \n\n30 September 2014\n \n \nScancell Holdings Plc\n \nScancell to Present at the 14th Annual Biotech in Europe Forum\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Dr Richard Goodfellow, Joint CEO of Scancell, is scheduled to present at the 14th Annual Biotech in Europe Forum for Global Partnering and Investment held in Basel, Switzerland on Tuesday 30 September 2014. \n \nDr Goodfellow will participate in the Oncology II - Next Generation Immunotherapies panel discussion at 2pm where he will be joined by leading cancer experts to discuss the increasing role of combination and targeted therapies.\n \nIn a corporate presentation at 4.30pm, Dr Goodfellow will provide an update on the progress of the SCIB1 clinical programme and the development of both the ImmunoBody® and Moditope® platforms. \n \nThe Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives.\n \n \nFor Further Information: \n \n\n\n\n\nScancell Holdings Plc \nDr Richard Goodfellow, Joint CEO \nProfessor Lindy Durrant, Joint CEO \n\n\n\n\n\n+44 (0) 74 2323 0 497 \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting \nSimon Conway\nMo Noonan\n\n\n\n\n\n+44 (0) 20 3727 1000\n\n\n\n\n \n \nAbout Scancell \n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. \n \nScancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cell...